ACRUX LIMITED — Capital/Financing Update 2024

Jun 27, 2024

==> picture [82 x 79] intentionally omitted <==

ASX Release

28 June 2024

Acrux secures short term funding facility with Radium Capital

Melbourne, Australia; Acrux Limited (ASX:ACR)

Acrux is pleased to announce that it has secured a non-dilutive short-term funding facility for its R&D Tax Incentive Rebate (‘RDTI’) with Radium Capital.

Acrux received $1,487,144 on 28 June 2024 broadly representing 80% of the estimated RDTI for the ten months to 30 April 2024. This short term facility will be repaid later in the 2024 calendar year when the FY24 RDTI is received from the Australian Tax Office and is secured against the RDTI receivable balance, attracting an interest charge of 1.33% per month.

This funding facility has been established to more closely match the timing of cashflow in relation to R&D expenditure and RDTI as an instrument to manage the Company’s working capital.

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au

Authorised for release by the Board of Acrux Limited.

For more information, please contact: Michael Kotsanis Acrux Limited CEO & Managing Director

P: + 61 3 8379 0100 E: michael.kotsanis@acrux.com.au